31 January 2024 - NICE has published evidence-based recommendations on the use of loncastuximab tesirine (Zynlonta) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after two or more systemic treatments.

Loncastuximab tesirine is recommended as an option for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after two or more systemic treatments, only if:

• They have previously had polatuzumab vedotin, or if polatuzumab vedotin is contra-indicated or not tolerated
• Sobi provides it according to the commercial arrangement

Read NICE technology appraisal guidance